4.25
+21.78%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hyloris Pharmaceuticals
Its shares trade on Euronext Brussels under the ticker HYL.BR. It has been listed since 29 June 2020. In the fiscal year to 31 December 2025, it reported revenue of €7.2m and a net loss of €6.3m. At that date it held total assets of €33.4m and shareholders' equity of €26.5m.
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege. The company went IPO on 2020-06-29. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Jun 2020
- Employees
- 24
- Website
- hyloris.com ↗
Leadership
Pay as last reported
- Mr. Stefan YeeNon-Executive Chairman of the Board€22,500
- Mr. Stijn Van RompayChief Executive Officer, Executive Director , Acting through SVR Management BV, since 2020€210,000
- Mr. Jean-Luc VandebroekChief Financial Officer, Acting through Finsys Management BV
- Mr. Dietmar AichhornChief Operating Officer
- Mr. Thomas JacobsenChief Business Development Officer, Executive Director, Acting through Jacobsen Management BV, since 2020
- Mr. Koenraad Van der ElstChief Legal Officer
- Mr. Leon Van RompayNon-Executive Director, Acting through Van Rompay Management BV€12,500
- Mr. Chris BuyseIndependent Director, Acting through Pienter Jan BV€17,500
- Mr. Marc FoidartIndependent Director, Acting through Noshaq Partners SCRL€22,500
- Mr. James GaleIndependent Director€17,500
- Dr. Carolyn MyersIndependent Director€17,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hyloris Pharmaceuticals SA focuses on cardiovascular products with wide therapeutic indications and dosage forms.
- The company has two partnered commercial-stage products: Sotalol IV and Maxigesic IV.
- Hyloris utilizes the 505(b)(2) regulatory pathway for reformulating approved pharmaceuticals efficiently.
Weaknesses
- Hyloris has only 24 full-time employees, which may limit operational capacity.
- The company's IPO was on 29 June 2020, indicating a relatively new market presence.
- Hyloris relies on partnered commercial-stage products, which could pose dependency risks.
Opportunities
- Expanding the 505(b)(2) regulatory pathway usage in the U.S. and other countries offers growth potential.
- Repurposing approved pharmaceuticals can lead to new market opportunities in cardiovascular treatments.
- The focus on reformulating existing drugs may reduce development costs and time to market.
Threats
- The pharmaceutical industry faces intense competition from established firms.
- Regulatory changes in the U.S. or other countries could impact the 505(b)(2) pathway.
- Dependency on partnered products may lead to revenue instability if partnerships end.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.